I call the meeting back to order.
Once again, welcome to meeting number 122 of the House of Commons Standing Committee on Health.
Before we begin, I'd like to ask all members and other in-person participants to consult the cards on the table for guidelines to prevent audio feedback incidents. Please take note of the following preventative measures in place to protect the health and safety of all participants, including the interpreters. Please use only the black, approved earpiece. The former grey earpieces must no longer be used. Please keep your earpiece away from all microphones at all times. When you're not using your earpiece, please place it face down on the sticker placed on the table for this purpose.
Thank you for your co-operation.
In accordance with our routine motion, I'm informing the committee that all remote participants have completed the required connection tests in advance of the meeting.
Pursuant to Standing Order 108(2) and the motion adopted on April 11, 2024, the committee is commencing its study of breast cancer screening guidelines.
I'd like to welcome our panel of witnesses.
We have, appearing as an individual, Dr. Michelle Nadler, breast medical oncologist and implementation scientist; representing Breast Cancer Canada, Kimberly Carson, CEO; representing the Coalition for Responsible Healthcare Guidelines, Dr. Shiela Appavoo, chair; and representing Dense Breasts Canada, Dr. Paula Gordon, volunteer medical adviser, clinical professor at the University of British Columbia.
To all of our witnesses, thank you for bearing with us. We had some technical difficulties and votes that caused the start to be delayed. We have resources until 6:30 eastern. That's when we will adjourn.
I understand Ms. Carson has another obligation that will require her to leave at 5:30, so we're going to start off the opening statements with Ms. Carson to make sure that we get it in.
Ms. Carson is here on behalf of Breast Cancer Canada.
Welcome to the committee. You have the floor.